Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation

Radiotherapy and Oncology

Volumn 72, Issue 2, 2004, Pages 231-241

  Rübe, Claudia E ^a   Wilfert, Falk ^a   Uthe, Daniela ^b   König, Jochem ^a   Liu, Li ^a,c   Schuck, Andreas ^b   Willich, Normann ^b   Remberger, Klaus ^a   Rübe, Christian ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Gemcitabine; IL 1 ; IL 6; Pneumonitis; Radiation enhancement; TNF

Indexed keywords

CYTOKINE; GEMCITABINE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IRRADIATION; LUNG TOXICITY; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANIMALS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; CYTOKINES; DEOXYCYTIDINE; FEMALE; HEMIBODY IRRADIATION; INTERLEUKIN-1; INTERLEUKIN-6; LUNG; MICE; MICE, INBRED C57BL; RADIATION-SENSITIZING AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 3543137676     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2004.05.004     Document Type: Article

References (50)

1. Attar E.C., Ervin T., Janicek M., et al. Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine. J Clin Oncol. 18:2000;697-698
2. Barlesi F., Doddoli C., Gimenez C., et al. Acute pulmonary toxicity due to gemcitabine: a role for asbetos exposure? Rev Mal Respir. 20:2003;201-206
3. Blackstock A.W., Lightfoot H., Kwock L., et al. Gemcitabine: in vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dosing schedule: preclinical observations relevant to gemcitabine clinical trials. Int J Radiat Oncol Biol Phys. 39:1997;205
4. Blackstock A.W., Lesser G.J., Fletcher-Steede J., et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 51:2001;1281-1289
5. Braakhuis B.J.M., Ruiz van Haperen V., Boven E., et al. Schedule-dependent anti-tumor effect of gemcitabine in vivo model systems. Semin Oncol. 22:1995;42-46
6. Clamon G., Herndon J., Cooper R., et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol. 17:1999;4-11
7. Cordell J.L., Falini B., Erber W.N., et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phospatase (APAAP complexes). J Histochem Cytochem. 32:1984;219-229
8. Curran W., Scott C., Langer C., et al. Phase III comparison of sequential versus concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer (NSCLC): initial report of the Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol. 19:2000;484a. Abstr. 1891
9. De Lavigerie B., Joasson J.M. Acute respiratory distress syndrome after antineoplastic chemotherapy. Probable role of gemcitabine. Presse Med. 30:2001;851-854
10. Fields M.T., Eisbruch A., Normolle D., et al. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′- deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 47:2000;785-791
11. Finkelstein J.N., Johnston C.J., Baggs R., Rubin P. Early alterations in extracellular matrix and transforming growth factor β gene expression in mouse lung indicative of late radiation fibrosis. Int J Radiat Oncol Biol Phys. 28:1994;621-631
12. Fossela F.V., Zinner R.G., Komaki R., et al. Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin: a phase I trial for patients with stage III non-small cell lung cancer. Proc Am Soc Clin Oncol. 20:2002;312
13. Franko A.J., Sharplin J., Ghahary A., Barcellos-Hoff M.H. Immunohistochhemical localization of transforming growth factor β and tumor necrosis factor α in the lungs of fibrosis-prone and 'non-fibrosing' mice during the latent period and early phase after irradiation. Radiat Res. 147:1997;245-256
14. Friedberg J.W., Neuberg D., Kim H., et al. Gemcitabine added to doxorubicin, bleomycin, and vinblastin for the treatment of de novo Hodgkin disease: unacceptable pulmonary toxicity. Cancer. 98:2000;978-982
15. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 17:1999;2692-2699
16. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics. CA Cancer J Clin. 51:2001;15-36
17. Grégoire V., Hittelman W.N., Rosier J.F., et al. Chemo-radiotherapy: radiosensitizing nucleoside analogues (review). Oncol Rep. 6:1999;949-957
18. Gregor A. Gemcitabine plus radiotherapy for non-small cell lung cancer. Semin Oncol. 24:1997;S8-S41
19. Groen H., Gregor A., van Putten J. Phase I trial of gemcitabine and high dose thoracic radiation in stage III non small cell lung cancer. Proc Am Soc Clin Oncol. 19:2000;539a. Abstr. 2123
20. Hammerer V., Schmitz N., Pauli G., et al. Interstitial lung disease in a patient given gemcitabine. Rev Pneumol Clin. 58:2002;23-26
21. Johnston C.J., Piedboeuf B., Baggs R., et al. Differences in correlation of mRNA gene expression in mice sensitive and resistant to radiation-induced pulmonary fibrosis. Radiat Res. 142:1995;197-203
22. Joschko M.A., Webster L.K., Groves J., et al. Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model. Radiat Oncol Invest. 5:1997;62-71
23. Kampf C., Revola A.J., Sandler S., et al. Effects of TNF-alpha, IFN-gamma and IL-beta on normal human bronchial epithelial cells. Eur Respir J. 14:1999;84-91
24. Latz D., Fleckenstein K., Eble M., et al. Radiosensitizing potential of gemcitabine (2′2′-difluoro-2′-deoxycytidine) within the cell cycle in vitro. Int J Radiat Oncol Biol Phys. 41:1998;875-882
25. Lawrence T.S., Chang E.Y., Hahn T.M., et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycitidine. Int J Radiat Oncol Biol Phys. 34:1996;867-872
26. Lawrence T.S., Eisbruch A., McGinn C.J., et al. Radiosensitization by gemcitabine. Oncology. 13:1999;55-60
27. Lawrence T.S., Davis M.A., Hough A., et al. The role of apoptosis in 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)-mediated radiosensitization. Clin Cancer Res. 7:2001;314-319
28. Lawrence T.S., Blackstock A.W., McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 13:2003;13-21
29. Le Chevalier T., Arriagada R., Quoix E., et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer. 10:1994;S239-S244
30. Marruchella A., Fiorenzano G., Merizzi A., et al. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J. 11:1998;504-506
31. Milas L., Fujii T., Hunter N., et al. Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. 59:1999;107-114
32. Mommens V., Bosquee L., D'Orio V. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis. Rev Med Liege. 58:2003;123-126
33. Mose S., Karapetian M., Juling-Pohlit L., et al. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. 20:2000;401-405
34. Nelson R., Tarassoff P. Dyspnoea with gemcitabine is commonly seen, often disease related, transient and rarely severe. Eur J Cancer. 31:1995;S197-S198
35. Ostruszka L.J., Shewach D.S. The role of cell cycle progression in radiosensitization by 2′,2′-difluoro-2′-deoxycytidine. Cancer Res. 60:2000;6080-6088
36. Pacini S., Milano F., Pinzani P., et al. Effects of gemcitabine in normal and transformed human lung cell cultures: cytotoxicity and increase in radiation sensitivity. Tumori. 85:1999;503-507
37. Pavlakis N., Bell D.R., Millward M.J., et al. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer. 80:1997;286-291
38. Rübe C.E., Uthe D., Schmid K.W., et al. Dose-dependent induction of transforming growth factor β (TGF-β) in the lung tissue of fibrosis-prone mice after thoracic irradiation. Int J Radiat Oncol Biol Phys. 47:2000;1033-1042
39. Rübe C.E., Wilfert F., Uthe D., et al. Modulation of radiation-induced tumor necrosis factor α (TNF-α) expression in the lung tissue by pentoxifylline. Radiother Oncol. 64:2002;177-187
40. Rübe CE, Uthe D, Wilfert F et al. The bronchiolar epithelium as a prominent source of pro-inflammatory cytokines after lung irradiation. Int J Radiat Oncol Biol Phys. Submitted for publication.
41. Rubin P., Johnston C.J., Williams J.P., et al. A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis. Int J Radiat Oncol Biol Phys. 33:1995;99-109
42. Sabria-Trias J., Bonnaud F., Sioniac M. Severe interstitial pneumonitis related to gemcitabine. Rev Mal Respir. 19:2002;645-647
43. Scalliet P., Goor C., Galdermans D., et al. Gemzar (gemcitabine) with thoracic radiotherapy: a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 17:1998;A1923
44. Shewach D.S., Lawrence T.S. Radiosensitization of human tumor cells by gemcitabine in vitro. Semin Oncol. 2:1995;68-71
45. Shewach D.S., Lawrence T.S. Gemcitabine and radiosensitization in human tumor cells. Invest New Drugs. 14:1996;257-263
46. Sörenson S., Glimelius B., Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol. 40:2001;327-339
47. Thomas A.L., Cox G., Sharma R.A., et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer. 36:2000;2329-2334
48. Trodella L., Granone P., Valente S., et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol. 20:2002;804-810
49. Van Putten J.W.G., Price A., van der Leest A.H.D., et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res. 9:2003;2472-2477
50. Vokes E., Leopold K., Herndon J., et al. A randomized phase II study of gemcitabine or placitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiation for unresectable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol. 18:1999;A1771